Key Takeaways Novo Nordisk will cut 9,000 jobs, about 11% of staff, to streamline operations and refocus on growth.The plan aims to save DKK 8B annually by 2026, reinvested in R&D, commercial execution and manufacturing.NVO cuts 2025 operating profit guidance to 4-10% due to restructuring costs and competitive pressures.Novo Nordisk (NVO) , now led by CEO Mike Doustdar, who only took office last month, announced a major restructuring plan aimed at streamlining operations, improving decision-making speed and ...

MADS CLAUS RASMUSSEN / Ritzau Scanpix / AFP / Getty Images Novo Nordisk expects the job reductions will save about $1.25 billion by the end of next year. Key Takeaways Novo Nordisk said it is laying off about about 9,000 positions or 11.5% of its workforce in a "transformation" of the drugmaker's business. The maker of Ozempic and Wegovy said the cuts are part of a plan to help the company grow its diabetes and weight-loss products. Novo Nordisk expects the job reductions will save about $1.25 billio ...

Pharmaceutical name Novo Nordisk A/S (NYSE:NVO), the maker of weight-loss drugs Wegovy and Ozempic, is in the spotlight today after announcing roughly 9,000 job cuts and slashing its full-year guidance. The company, which is seeing increased competition, is hoping to save $1.3 billion annually through its major restructuring plan. BMO Securities reiterated its "market perform" rating after news. This comes just one day after Bernstein Securities upgraded the stock to "outperform" from "market perform," citi ...

公司战略调整 - 诺和诺德宣布全球转型计划 旨在简化组织结构 加快决策速度 并将资源重新聚焦于糖尿病和肥胖症领域的增长机会 [2] - 公司将在全球范围内裁员9000人 占员工总数11% 以每年节省80亿丹麦克朗（约12.6亿美元）成本 [2][3] - 裁员覆盖公司各个部门 包括后勤支持和总部职能 节约资本将重新投入糖尿病和肥胖症领域的商业执行和研发项目 [4] 管理层与组织变革 - 新任首席执行官杜斯特达尔指出市场正在演变 特别是肥胖领域变得更加竞争性和消费者导向 需要培养更绩效导向的文化 [4] - 公司进行高层调整 包括更换CEO 首席科学官和国际运营执行副总裁 [7] - 中国区业务架构调整 肥胖症业务部与胰岛素组合并为全新的肥胖症与糖尿病事业部（DOD）以促进协同效应 [7] 财务与市场竞争 - 上半年营收1549.44亿丹麦克朗（约229.26亿美元）同比增长18% 经营利润722亿丹麦克朗同比增长29% 但整体营收增速较上年同期下滑 [6] - 司美格鲁肽取代默沙东K药成为全球新药王 但面临礼来替尔泊肽的竞争压力 后者在疗效上优于司美格鲁肽 [5][6] - 公司下调2025年全年业绩预期 受市场竞争加剧和仿制药冲击等因素影响 [6] 行业动态 - 全球生物制药行业裁员加剧 上半年130家企业累计裁减13470名员工 较2024年同期增长31% [9] - 多家跨国药企启动裁员计划 包括CSL集团裁员3000人（占15%）默沙东裁员6000人（占8%）拜耳累计减员1.1万人 梯瓦裁员2900人（占8%）[9][10] - 减肥药市场规模预计达600亿美元 除GLP-1药物外 市场对其他机制减肥药物兴趣增加 [6]

My previous cautious thesis for Novo Nordisk ( NVO ) appears to have aged well; the stock has dropped by more than 50% since last July, and is now, in my opinion, far too cheap to ignore. Add in some impressive fundamentals—an 18% increase inI am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and intern ...

BREAKING: Futures Rise As Oracle Skyrockets, PPI Inflation TameNovo Nordisk (NVO) announced a "sweeping transformation" Wednesday as the drugmaker contends with knockoffs chipping away at its blockbuster drugs Ozempic and Wegovy.The Danish company will eliminate 9,000 jobs, or 11% of its workforce, in an effort to deliver 8 billion Danish kroner in annualized savings by the end of 2026. That translates to roughly $1.26 billion, based on today's exchange rates.As a result, Novo also trimmed its operating pro ...

The company downgraded its guidance for the second time in six weeks as it announced a restructuring plan. ...

PresentationPeter Birtles Good afternoon, ladies and gentlemen. I'd like to thank you for coming out today on what is really not a very pleasant day. So we appreciate the fact that so many of you made the effort to get here. My name is Peter Birtles, I'm the Chair of Metcash Limited. And on behalf of the Board and management of the company, I extend a very warm welcome to you to today's 2025 Annual General Meeting. Before we commence, I'd like to acknowledge the Traditional Custodians of the lands on which ...

诺和诺德不是近期唯一一家裁员的跨国药企，但是是裁员规模 最大的一家。就在2025年7月，Moderna和默沙东均宣布将 在全球裁员，涉及人数分别约为1000人和6000人。 作者： 张铃 封图：图虫创意 9月10日，诺和诺德宣布裁员约9000人，预计到2026年底每年节省80亿丹麦克朗（约合89.4亿元人 民币）。 同时，诺和诺德将2025年营业利润增长预期下调至4%—10%，此前预期为10%—16%。 裁员是诺和诺德转型计划的一部分。诺和诺德称，决定转型是因为其"近期增长放缓"，故计划简化 组织结构、提高决策速度，节省的资金将投入糖尿病和肥胖症治疗领域的增长机遇。 目前，诺和诺德在全球有78400名员工，此次裁员计划人数约占总员工的11%。据悉，裁员名单中 超过一半将来自诺和诺德的总部丹麦。 截至2024年底，诺和诺德在华员工为6978人。诺和诺德暂未公布丹麦以外区域裁员数量。经济观 察报函询诺和诺德中国区受此次裁员影响情况，截至发稿未获回复。 诺和诺德是一家有102年历史的跨国制药巨头，最初靠胰岛素产品起家，百年来也一直在糖尿病领 域有所建树。近几年，其以横空出世的减肥药司美格鲁肽引领着新一轮全球范围内火 ...

Let me put it bluntly: the US economy isn't in the best shape. Market isn't best economic indicator, and that's why my words go contrary to the all-time highs ( SP500 ).I’m a Financial Analyst at a Fortune 500 company, investing with a long runway—30 years to retirement and plenty of compounding ahead. I write about building a thoughtful portfolio that balances strong growth potential with solid fundamentals. My focus is on high-quality businesses, mostly in the U.S. and Europe—companies with staying power, ...